In Ovations Holdings, Inc. has concluded negotiations and due diligence and has entered into a sales and marketing agreement with Regulon, Inc. for the marketing and sale of Regulon's anti-cancer therapies. The parties will leverage INOH's access to markets including the Caribbean in order to broaden the awareness and sale of their cancer detection and treatment products. Regulon designs and produces the following anti-cancer drugs: LipoPlatin, LipoXal, LipoVil-12.

Regulon has developed a unique liposome encapsulation technology applicable to drugs such as cisplatin, a cytotoxic agent, small molecules, peptides, proteins and viruses aiming at improving human lives and reducing the side effects of chemotherapy known to exacerbate the quality of life of cancer patients. Regulon is currently engaged in active sales. Recent studies showed that platinum-based chemotherapy drugs share is growing.

The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon's LipoPlatin.